過氧化物酶體增殖物激活受體γ(PPARg)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Peroxisome Proliferator Activated Receptor Gamma (PPARg) ,etc. by FLIA (Flow Luminescence Immunoassay)
PPAR-G; PPARG1; PPARG2; NR1C3; Glitazone Receptor; Nuclear Receptor Subfamily 1 Group C Member 3
(注:?jiǎn)未位鞙y(cè)多因子不超過8個(gè)指標(biāo) )
- 編號(hào)LMA886Hu
 - 物種Homo sapiens (Human,人)相同的名稱,不同的物種。
 - 實(shí)驗(yàn)方法雙抗夾心
 - 反應(yīng)時(shí)長(zhǎng)3.5h
 - 檢測(cè)范圍0.01-10ng/mL
 - 靈敏度最小可檢測(cè)劑量小于等于0.003 ng/mL.
 - 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
 - 下載英文說明書 中文說明書
 - 規(guī)格8指標(biāo)數(shù)7指標(biāo)數(shù)6指標(biāo)數(shù)5指標(biāo)數(shù)4指標(biāo)數(shù)3指標(biāo)數(shù)2指標(biāo)數(shù)1指標(biāo)數(shù)
 - 價(jià)格¥ 2359¥ 2449¥ 2586¥ 2767¥ 2948¥ 3221¥ 3629¥ 4536 添加到價(jià)格計(jì)算器 計(jì)算器
 - 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
 
特異性
                        本試劑盒用于檢測(cè)過氧化物酶體增殖物激活受體γ(PPARg)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
                        由于受到技術(shù)及樣本來源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
                    
回收率
分別于定值血清及血漿樣本中加入一定量的過氧化物酶體增殖物激活受體γ(PPARg)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) | 
| serum(n=5) | 92-101 | 96 | 
| EDTA plasma(n=5) | 90-99 | 96 | 
| heparin plasma(n=5) | 97-105 | 101 | 
| sodium citrate plasma(n=5) | 79-103 | 95 | 
精密度
                    精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100 
                    批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
                    批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
                    批內(nèi)差: CV<10% 
                    批間差: CV<12% 
線性
在定值血清及血漿樣本內(nèi)加入適量的過氧化物酶體增殖物激活受體γ(PPARg)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中過氧化物酶體增殖物激活受體γ(PPARg)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 | 
| serum(n=5) | 94-101% | 89-101% | 80-97% | 78-104% | 
| EDTA plasma(n=5) | 93-102% | 81-102% | 88-95% | 80-104% | 
| heparin plasma(n=5) | 89-99% | 91-102% | 87-95% | 80-88% | 
| sodium citrate plasma(n=5) | 80-99% | 96-105% | 94-102% | 93-105% | 
穩(wěn)定性
                    經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
                    為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
                
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
                            2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
                                37°C酶標(biāo)板振蕩器孵育90分鐘;
                            3. 磁吸甩干,加檢測(cè)溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
                            4. 磁吸洗板3次;
                            5. 加檢測(cè)溶液B100μL,37°C振動(dòng)孵育30分鐘;
                            6. 磁吸洗板3次;
                            7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將過氧化物酶體增殖物激活受體γ(PPARg)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的過氧化物酶體增殖物激活受體γ(PPARg)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的過氧化物酶體增殖物激活受體γ(PPARg)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的過氧化物酶體增殖物激活受體γ(PPARg)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) | 
| APA886Hu01 | 過氧化物酶體增殖物激活受體γ(PPARg)活性蛋白 | Cell?culture;?Activity?Assays. | 
| RPA886Hu02 | 過氧化物酶體增殖物激活受體γ(PPARg)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| RPA886Hu01 | 過氧化物酶體增殖物激活受體γ(PPARg)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| PAA886Hu02 | 過氧化物酶體增殖物激活受體γ(PPARg)多克隆抗體 | WB; IHC; ICC; IP. | 
| PAA886Hu01 | 過氧化物酶體增殖物激活受體γ(PPARg)多克隆抗體 | WB; IHC; ICC; IP. | 
| LAA886Hu71 | 過氧化物酶體增殖物激活受體γ(PPARg)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. | 
| MAA886Hu22 | 過氧化物酶體增殖物激活受體γ(PPARg)單克隆抗體 | WB; IHC; ICC; IP. | 
| SEA886Hu | 過氧化物酶體增殖物激活受體γ(PPARg)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. | 
| LMA886Hu | 過氧化物酶體增殖物激活受體γ(PPARg)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. | 
| KSA886Hu01 | 過氧化物酶體增殖物激活受體γ(PPARg)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". | 
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) | 
| Neuroscience Letters | Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis[Pubmed: 24021801] | 
| J Cell Biochem. | Nonivamide enhances miRNA let‐7d expression and decreases adipogenesis PPARγ expression in 3T3‐L1 cells[Pubmed:25704235] | 
| Osteoarthritis Cartilage | Establishment of a rabbit model to study the influence of advanced glycation end products accumulation on osteoarthritis and the protective effect of pioglitazone[PubMed: 26321377] | 
| J Clin Diagn Res. | Evaluation of Protein Kinase Cβ and PPARγ Activity in Diabetic Rats Supplemented with Momordica charantia[pmc:PMC4866090] | 
| Journal of Clinical&Diagnostic Research | Evaluation?of?Protein?Kinase?Cβ and PPARγ?Activity?in?Diabetic?RatsSupplemented?with?Momordica?charantia.[pubmed:27190792] | 
| Osteoarthritis?and?Cartilage | Establishment?of a?rabbit?model?to?study?the?influence?of?advanced?glycation?end?productsaccumulation?on?osteoarthritis?and the?protective?effect?of pioglitazone.[pubmed:26321377] | 
| Neuroscience Letters | Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis[pubmed:28483651] | 
| European?Journal?of?Immunology | Engulfment of Hb‐activated platelets differentiates monocytes into pro‐inflammatory macrophages in PNH patients[Pubmed:29677388] | 
| Histochemistry and?Cell Biology | Simpson–Golabi–Behmel syndrome human adipocytes reveal a changing phenotype throughout differentiation[Pubmed:29574488] | 
| molecular and cellular biochemistry | Maternal omega-3 fatty acids and vitamin E improve placental angiogenesis in late-onset but not early-onset preeclampsia[Pubmed: 31420792] | 
| Nutrients.? | Hyperglycemia Changes Expression of Key Adipogenesis Markers (C/EBPα and PPAR?) and Morphology of Differentiating Human Visceral Adipocytes[Pubmed: 31398873] | 
| journal of biochemical and molecular toxicology | Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells[Pubmed: 31916655] | 
| J Cosmet Dermatol | In?\vitro effect of pine bark extract on melanin synthesis, tyrosinase activity, production of endothelin?\1 and PPAR in cultured melanocytes exposed to Ultraviolet??-[33960120] | 
| American Chemical Society | TRPA1 Agonist Cinnamaldehyde Decreases Adipogenesis in 3T3-L1 Cells More Potently than the Non-agonist Structural Analog Cinnamyl Isobutyrate[33403292] | 
| PLoS One | Quantitative real-time measurement of endothelin-1-induced contraction in single non-activated hepatic stellate cells[34343209] | 
| Prostaglandins Leukot Essent Fatty Acids | Maternal Vitamin D Deficiency Reduces Docosahexaenoic Acid, Placental Growth Factor and Peroxisome Proliferator Activated Receptor Gamma levels in the Pup?…[34768025] | 
| Food and Chemical Toxicology | Melatonin attenuates cisplatin-induced acute kidney injury in mice: Involvement of PPARα and fatty acid oxidation[Pubmed:35367536] | 


